The main hair related items of interest were:
- Shiseido’s new research center in Japan, already discussed on this blog before.
- Replicel anticipating the start of Phase 2 trials for its RCH-01 hair regeneration technology in Germany in the fourth quarter of 2014.
- Shiseido also starting Phase 2 trials in Japan in the fourth quarter of 2014. I was surprised to read that Shiseido is the world’s fourth largest cosmetics company, further lending credibility to Replicel’s technology.
Note that on Replicel’s website, they still have a page where one can volunteer to sign up for their clinical trials provided one resides in Austria or Germany. It seems like they are limiting enrollment to 160 male volunteers.
The company’s losses increased modestly compared to the same period last year, but there seem to be valid reasons for this as explained in their announcement. Nevertheless, the company’s stock price declined by over 7 percent today as of the time of writing this post.
Replicel (REPCF)’s 1-year daily stock price and volume traded (in 000 shares per day) charts from nasdaq.com:
According to a June 2014 report from Allied Analytics, the global regenerative medicine market is expected to grow from $16.4 billion in 2013 to $67.6 billion in 2020 — a stellar outlook. Besides hair regeneration, Replicel is also involved in tendon regeneration (RCT-01) and skin regeneration (RCS-01) technologies. The company has stated that its tendon regeneration product is its most important focus, while its skin regeneration product is still in an early research phase of development.
Considering that Replicel uses autologous (one’s own) cells in the regeneration process, the chances of any kind of serious side effects seem minimal. This has favorable implications for the company passing safety requirements during Phase 2 trials.